Global Takayasu Arteritis Registry (GITA)
Takayasu's Arteritis Global Registry
The registry will collect past and ongoing medical information from people with Takayasu arteritis worldwide to see which treatments and patient features relate to better outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Marmara University Academic / other |
| Locations | 2 sites (Istanbul, Istanbul and 1 other locations) |
| Trial ID | NCT07558382 on ClinicalTrials.gov |
What this trial studies
This is an international, multicenter, non-interventional registry that collects both retrospective and prospective longitudinal data on people with Takayasu arteritis. Participating centers upload routine demographic, clinical, laboratory, and imaging data plus details of diagnostic methods, management, and therapies. The project enables comparison of patient characteristics, treatment approaches, and prognoses across centers and regions. Data are gathered during usual clinical care and patients provide informed consent for inclusion.
Who should consider this trial
Good fit: People who meet the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis and can give informed consent (or have a legal representative) are eligible, whether enrolled retrospectively or after diagnosis moving forward.
Not a fit: Patients who do not meet the formal diagnostic criteria or who cannot or will not provide informed consent are not eligible and are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the registry could reveal patterns in disease course and treatment outcomes that help clinicians make better care decisions for people with Takayasu arteritis.
How similar studies have performed: Other vasculitis and Takayasu registries have provided useful natural history and outcome data, so this approach has precedent.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Each patient must fullfill the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis. * Patients (or legally acceptable representatives of subjects enrolled) have to * provide informed and free agreement to participate in the study and to disclose any medical event to the investigator. The parents or legally acceptable representative and the adolescent subject must be willing and able to comply with the study protocol requirements for the duration of the study * freely sign written and dated informed consent after being duly informed of the nature, significance, and implications of the study; * be informed that the patient enrolled may withdraw consent at any time without prejudice to future medical care. Exclusion Criteria: Patients must be excluded from the study when the following criteria are observed: * The patient does not full-fill the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis * informed consent/assent is not provided and signed
Where this trial is running
Istanbul, Istanbul and 1 other locations
- Marmara University School of Medicine — Istanbul, Istanbul, Turkey (Türkiye) (Recruiting)
- Marmara University School of Medicine — Istanbul, Istanbul, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Fatma Alibaz-Oner, Professor, MD
- Email: falibaz@gmail.com
- Phone: +902166574545
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.